Cardiovascular Systems’ (CSI) Predator 360° prospective single-centre clinical study has demonstrated beneficial long-term durability of the Predator 360 PAD system in treating peripheral arterial disease (PAD), or blockages in leg arteries.
Predator 360 PAD systems are percutaneous orbital atherectomy systems indicated for use as therapy in patients with occlusive atherosclerotic disease in peripheral arteries and stenotic material from artificial arteriovenous dialysis fistulae.
The study enrolled 46 patients, who underwent primary intervention with the Predator 360° orbital technology followed by adjunctive balloon inflations if necessary, as assisted by the physician.
Treatment with Predator 360° showed a low (10.9%) reintervention rate within 12 months, compared to 40 to 74% of dissection rates for balloon angioplasty.
Principal investigator of the study Dr. Prakash Makam said 12-month data shows the Predator 360° is a durable solution, resulting in modified lesion compliance, and its unique orbital mechanism of action with differential sanding safely removes resistant plaque, reducing the need for high-pressure balloon inflation and stenting.